Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
75 participants
INTERVENTIONAL
2003-10-31
2006-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pegvisomant/ Sandostatin LAR
Sandostatin LAR
Pegvisomant
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Received previous radiation and/or surgical treatment for their GH (Growth Hormone) producing pituitary adenoma and have required medical therapy due to failure to normalize GH (Growth Hormone) and/or IGF-I as a result of their primary treatment
* Patients that been receiving Sandostatin LAR for a minimum of 6 months prior to enrollment
Exclusion Criteria
* Patients on current medical therapy other than Sandostatin LAR
* AST/ALT \>= 3xULN (upper limits of normal)
* Pituitary adenoma within 3mm of optic chiasm confirmed by recent MRI
* Visual field defects (except post-surgical stable residual defects)
* Unable to self administer drug
* Radiotherapy within 12 months of entering the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
Boston, Massachusetts, United States
Pfizer Investigational Site
Chapel Hill, North Carolina, United States
Pfizer Investigational Site
Charlottesville, Virginia, United States
Pfizer Investigational Site
Darlinghurst, New South Wales, Australia
Pfizer Investigational Site
Fitzroy, Victoria, Australia
Pfizer Investigational Site
Fizroy, Victoria, Australia
Pfizer Investigational Site
Rio de Janeiro, Rio de Janeiro, Brazil
Pfizer Investigational Site
São Paulo, São Paulo, Brazil
Pfizer Investigational Site
Halifax, Nova Scotia, Canada
Pfizer Investigational Site
Halifax, Nova Scotia, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Montpellier, , France
Pfizer Investigational Site
Nice, , France
Pfizer Investigational Site
Berlin, , Germany
Pfizer Investigational Site
Dresden, , Germany
Pfizer Investigational Site
Hanover, , Germany
Pfizer Investigational Site
Genova, , Italy
Pfizer Investigational Site
Messina, , Italy
Pfizer Investigational Site
Milan, , Italy
Pfizer Investigational Site
Torino, , Italy
Pfizer Investigational Site
Mexico City, Mexico City, Mexico
Pfizer Investigational Site
Col La Raza, Mexico DF, Mexico
Pfizer Investigational Site
Nijmegen, , Netherlands
Pfizer Investigational Site
Oslo, , Norway
Pfizer Investigational Site
L'Hospitalet de Llobregat, Barcelona, Spain
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Belfast, Antrim, United Kingdom
Pfizer Investigational Site
Leeds, , United Kingdom
Pfizer Investigational Site
London, , United Kingdom
Pfizer Investigational Site
London, , United Kingdom
Pfizer Investigational Site
Manchester, , United Kingdom
Pfizer Investigational Site
Oxford, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A6291006
Identifier Type: -
Identifier Source: secondary_id
PEGA-0435-005
Identifier Type: -
Identifier Source: org_study_id